The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most ...

Get the detailed quarterly/annual income statement for Vanda Pharmaceuticals Inc. (VNDA). Find out the revenue, expenses and profit or loss over the last fiscal year.

Vanda Pharmaceuticals Inc. (VNDA) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

VNDA is developing VGT-1849A, a novel antisense oligonucleotide (ASO)-based JAK2 inhibitor for treating PV and other JAK2-driven hematologic malignancies. VNDA's Zacks Rank & Rising Estimates.

Investors in Vanda Pharmaceuticals Inc (Symbol: VNDA) saw new options begin trading this week, for the December 21st expiration. One of the key data.

Vanda Pharmaceuticals (VNDA) is a net-net opportunity with a market cap of $250mm and $387mm in net cash. The market is worried about declining sales of the company's top drug. Despite the ...

It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the.

The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held in Scottsdale, Arizona, from ...